AGIOS PHARMACEUTICALS, INC. (AGIO)

Nasdaq · Pharmaceutical Preparations

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

a public American pharmaceutical company

Corporate structure

7 entities across 7 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-12 — see the exhibit.

Which other public companies file entities in the same places:

Massachusetts1 Bermuda1 Switzerland1 The Netherlands1 Germany1 Italy1 France1

Subsidiaries of AGIOS PHARMACEUTICALS, INC. as disclosed in its SEC filing
Entity	Jurisdiction	Note
Agios Securities Corporation	Massachusetts
Agios Limited	Bermuda	offshore centre
Agios International Sarl (GmbH)	Switzerland
Agios Netherlands B.V.	The Netherlands
Agios Germany GmbH	Germany
Agios Italy S.R.L.	Italy
Agios France SARL	France

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

2 / 7

FAILReturn on assets positiveROA -31.8%
FAILOperating cash flow positiveOCF -373M
FAILReturn on assets improving40.5% → -31.8%
PASSCash flow exceeds earningsOCF -373M vs NI -413M
FAILLong-term debt ratio fallingno debt reported
FAILCurrent ratio improving11.90 → 11.46
FAILNo share dilution58M → 58M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.02× → 0.04×

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$203.2M	−$327.4M	−$305.7M	—	68,997,879
FY2021	$0	$1.6B	−$413.1M	—	60,447,346
FY2022	$14.2M	−$231.8M	−$314.4M	—	54,789,435
FY2023	$26.8M	−$352.1M	−$297.1M	—	55,651,487
FY2024	$36.5M	$673.7M	−$391.5M	—	57,889,255
FY2025	$54.0M	−$412.8M	−$377.3M	—	57,972,004

Ownership flow

12 institutions tracked — 8 added, 3 reduced.

Institutional holders of AGIOS PHARMACEUTICALS, INC. and their share-count change
Manager	Kind	Shares	Change	Value
BlackRock, Inc.	Index	6,455,997	+701,040	$239.6M
AQR CAPITAL MANAGEMENT LLC	Hedge fund	684,340	+647,930	$25.4M
WELLINGTON MANAGEMENT GROUP LLP	Active fund	20,875	−620,611	$774,671
Point72 Asset Management, L.P.	Hedge fund	506,344	+476,944	$18.8M
STATE STREET CORP	Index	3,533,633	+168,754	$131.1M
JPMORGAN CHASE & CO	Active fund	360,056	+148,198	$13.8M
CITADEL ADVISORS LLC	Hedge fund	913,187	+143,774	$33.9M
GEODE CAPITAL MANAGEMENT, LLC	Index	1,574,268	+106,358	$58.4M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	218,966	−79,817	$8.1M
FMR LLC	Active fund	39,072	+29,951	$1.4M
MORGAN STANLEY	Active fund	963,256	−4,269	$35.7M
BANK OF AMERICA CORP /DE/	Active fund	507,869	−31	$18.8M

From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.

Identity

CIK: 0001439222
SIC: 2834 · Pharmaceutical Preparations
Incorporated: DE
Headquarters: CAMBRIDGE, MA
Founded: 2008-00-00

Ownership

Institutional: 112.3%
Institutions: 318
Insiders: 1.1%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Other pharmaceutical preparations companies

AGIOS PHARMACEUTICALS, INC. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.

PFIZER INCPFE JOHNSON & JOHNSONJNJ Merck & Co., Inc.MRK AbbVie Inc.ABBV ELI LILLY & CoLLY BRISTOL MYERS SQUIBB COBMY

Questions about AGIOS PHARMACEUTICALS, INC.

How many subsidiaries does AGIOS PHARMACEUTICALS, INC. file with the SEC?: 7, listed in its most recent exhibit 21. They are incorporated across 7 jurisdictions, led by Massachusetts, Bermuda, Switzerland. 1 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is AGIOS PHARMACEUTICALS, INC. financially healthy?: AGIOS PHARMACEUTICALS, INC. scores 2 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of AGIOS PHARMACEUTICALS, INC.?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BlackRock, Inc. (adding), STATE STREET CORP (adding), GEODE CAPITAL MANAGEMENT, LLC (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.

Corporate structure

7 entities across 7 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-12 — see the exhibit.

Entity

Jurisdiction

Note

Agios Securities Corporation

Massachusetts

Agios Limited

Bermuda

offshore centre

Agios International Sarl (GmbH)

Switzerland

Agios Netherlands B.V.

The Netherlands

Agios Germany GmbH

Germany

Agios Italy S.R.L.

Italy

Agios France SARL

France

Financial health

Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

2 / 7

FAILReturn on assets positiveROA -31.8%
FAILOperating cash flow positiveOCF -373M
FAILReturn on assets improving40.5% → -31.8%
PASSCash flow exceeds earningsOCF -373M vs NI -413M
FAILLong-term debt ratio fallingno debt reported
FAILCurrent ratio improving11.90 → 11.46
FAILNo share dilution58M → 58M shares
FAILGross margin improvingno gross profit reported
PASSAsset turnover improving0.02× → 0.04×

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2020	$203.2M	−$327.4M	−$305.7M	—	68,997,879
FY2021	$0	$1.6B	−$413.1M	—	60,447,346
FY2022	$14.2M	−$231.8M	−$314.4M	—	54,789,435
FY2023	$26.8M	−$352.1M	−$297.1M	—	55,651,487
FY2024	$36.5M	$673.7M	−$391.5M	—	57,889,255
FY2025	$54.0M	−$412.8M	−$377.3M	—	57,972,004

Ownership flow

12 institutions tracked — 8 added, 3 reduced.

Institutional holders of AGIOS PHARMACEUTICALS, INC. and their share-count change
Manager	Kind	Shares	Change	Value
BlackRock, Inc.	Index	6,455,997	+701,040	$239.6M
AQR CAPITAL MANAGEMENT LLC	Hedge fund	684,340	+647,930	$25.4M
WELLINGTON MANAGEMENT GROUP LLP	Active fund	20,875	−620,611	$774,671
Point72 Asset Management, L.P.	Hedge fund	506,344	+476,944	$18.8M
STATE STREET CORP	Index	3,533,633	+168,754	$131.1M
JPMORGAN CHASE & CO	Active fund	360,056	+148,198	$13.8M
CITADEL ADVISORS LLC	Hedge fund	913,187	+143,774	$33.9M
GEODE CAPITAL MANAGEMENT, LLC	Index	1,574,268	+106,358	$58.4M
PRICE T ROWE ASSOCIATES INC /MD/	Active fund	218,966	−79,817	$8.1M
FMR LLC	Active fund	39,072	+29,951	$1.4M
MORGAN STANLEY	Active fund	963,256	−4,269	$35.7M
BANK OF AMERICA CORP /DE/	Active fund	507,869	−31	$18.8M

Questions about AGIOS PHARMACEUTICALS, INC.

How many subsidiaries does AGIOS PHARMACEUTICALS, INC. file with the SEC?

7, listed in its most recent exhibit 21. They are incorporated across 7 jurisdictions, led by Massachusetts, Bermuda, Switzerland. 1 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.

Is AGIOS PHARMACEUTICALS, INC. financially healthy?

AGIOS PHARMACEUTICALS, INC. scores 2 out of 7 on the Piotroski F-score. Only 7 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of AGIOS PHARMACEUTICALS, INC.?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are BlackRock, Inc. (adding), STATE STREET CORP (adding), GEODE CAPITAL MANAGEMENT, LLC (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.